Muscle-Targeting Antibody-Oligonucleotide Complexes for Myotonic Dystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for myotonic dystrophy type 1 (DM1) lack an effective therapeutic option, as existing methods fail to specifically target and inhibit the expression of the disease-associated DMPK allele in muscle cells, leading to persistent muscle degeneration and associated symptoms.
Innovation Solution
Development of muscle-targeting complexes comprising antibodies specifically binding to the transferrin receptor on muscle cells, which internalize molecular payloads such as oligonucleotides to inhibit the expression of the expanded DMPK allele, utilizing covalent linkers for controlled release of the payloads within muscle cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for myotonic dystrophy, then general symptom management is provided, but specific inhibition of DMPK allele expression in muscle cells is not achieved
Solution Approach 1:
The patent applies local quality by creating a complex with differentiated functional components: the antibody portion provides muscle cell specificity (local targeting), while the oligonucleotide portion provides DMPK allele inhibition (local molecular action). This division allows the treatment to be both specific to muscle cells and effective at inhibiting the disease allele, resolving the contradiction between reliability and adaptability.
Solution Approach 2:
The patent uses an antibody as an intermediary molecule that mediates between the administration route and the target oligonucleotide. The antibody binds to muscle cell surface antigens and delivers the oligonucleotide payload specifically to muscle cells, enabling specific inhibition of DMPK allele expression without affecting other tissues. This intermediary approach resolves the contradiction by providing both targeting specificity and therapeutic effectiveness.
2Manufacturing precision
If molecular payloads are delivered to muscle cells, then DMPK expression is inhibited, but delivery specificity to muscle cells must be ensured
Solution Approach 1:
The patent employs composite materials by combining an antibody molecule with an oligonucleotide payload to create a functional complex. The antibody provides muscle cell targeting capability while the oligonucleotide provides the therapeutic function of inhibiting DMPK expression. This composite structure achieves precise delivery to muscle cells while the complexity is managed through the natural modular structure of the antibody-oligonucleotide conjugate.
3Ease of manufacture
If oligonucleotides are released inside muscle cells, then DMPK allele expression is inhibited, but controlled release mechanism is required
Solution Approach 1:
The patent applies self-service by designing the complex so that endosomal proteases naturally present in the cell automatically cleave the linker between the antibody and oligonucleotide components. This self-cleaving mechanism eliminates the need for external triggering or complex controlled release systems, while still achieving precise intracellular release of the oligonucleotide payload. The simplicity of the protease-cleavable linker resolves the contradiction between ease of manufacture and controlled release timing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The muscle-targeting complexes effectively reduce DMPK expression levels in muscle tissues, demonstrating potential for treating myotonic dystrophy by specifically targeting and inhibiting the disease-associated allele, thereby mitigating muscle degeneration and associated symptoms.
Implementation Method 1
complexes provided herein comprise muscle-targeting agents (e.g., muscle targeting antibodies) that specifically bind to receptors on the surface of muscle cells
Implementation Method 2
the complexes are taken up into the cells via a receptor mediated internalization
Implementation Method 3
the oligonucleotides are released by endosomal cleavage of covalent linkers connecting oligonucleotides and muscle-targeting agents of the complexes
Data Source
AI summary
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.